يعرض 961 - 980 نتائج من 14,056 نتيجة بحث عن '(( significantly increased decrease ) OR ( significant ((all decrease) OR (fold decrease)) ))', وقت الاستعلام: 0.42s تنقيح النتائج
  1. 961

    The prognostic value of the neutrophil-percentage-to-albumin ratio for all-cause and cardiovascular mortality in chronic kidney disease stages G3a to G5: insights from NHANES 2003–... حسب Jialing Rao (20354623)

    منشور في 2025
    "…High levels NPAR exhibited a significantly elevated risk of both all-cause and CVD mortality in the fully adjusted model. …"
  2. 962

    DataSheet1_Associations of serum folate and vitamin B12 levels with all-cause mortality among patients with metabolic dysfunction associated steatotic liver disease: a prospective... حسب Jiaxin Zhu (446571)

    منشور في 2024
    "…When their serum concentrations were below the median level, the risk of all-cause mortality decreased with increasing concentration, reaching a lowest risk around the median level, and then leveled off. …"
  3. 963

    High Stability, Piezoelectric Response, and Promising Photocatalytic Activity on the New Pentagonal CGeP<sub>4</sub> Monolayer حسب José A. S. Laranjeira (18870824)

    منشور في 2024
    "…This suggests potential photocatalytic behavior across all tensile strain regimes and significant compression levels (ε = 0% to −8%). …"
  4. 964

    High Stability, Piezoelectric Response, and Promising Photocatalytic Activity on the New Pentagonal CGeP<sub>4</sub> Monolayer حسب José A. S. Laranjeira (18870824)

    منشور في 2024
    "…This suggests potential photocatalytic behavior across all tensile strain regimes and significant compression levels (ε = 0% to −8%). …"
  5. 965

    AC-LPN circuit control high temperature induced increase of evening sleep. حسب Xin Yuan (174619)

    منشور في 2024
    "…(D–G) Optogenetic activation of ppkACs with CsChrimson (<i>Ppk-LexA>LexAop-CsChrimson</i>) increases LPN activity in vivo (D). Scale bars, 10 mm. …"
  6. 966

    Univariate analyses. حسب Zachary E. M. Giovannini-Green (22008277)

    منشور في 2025
    "…ED utilization by individuals with psychotic disorders increased during the first year of the COVID-19 pandemic, while ED use by most Canadians decreased. …"
  7. 967

    Overview of individuals in the study. حسب Zachary E. M. Giovannini-Green (22008277)

    منشور في 2025
    "…ED utilization by individuals with psychotic disorders increased during the first year of the COVID-19 pandemic, while ED use by most Canadians decreased. …"
  8. 968

    Multivariate analyses. حسب Zachary E. M. Giovannini-Green (22008277)

    منشور في 2025
    "…ED utilization by individuals with psychotic disorders increased during the first year of the COVID-19 pandemic, while ED use by most Canadians decreased. …"
  9. 969
  10. 970
  11. 971
  12. 972

    Table 3_Association between platelet-to-red cell distribution width ratio and all-cause mortality in critically ill patients with non-traumatic cerebral hemorrhage: a retrospective... حسب Rongrong Lu (322302)

    منشور في 2024
    "…As PRR increased, restrictive cubic splines showed a progressive decrease in the probability of all-cause mortality. …"
  13. 973

    Table 1_Association between platelet-to-red cell distribution width ratio and all-cause mortality in critically ill patients with non-traumatic cerebral hemorrhage: a retrospective... حسب Rongrong Lu (322302)

    منشور في 2024
    "…As PRR increased, restrictive cubic splines showed a progressive decrease in the probability of all-cause mortality. …"
  14. 974

    Table 2_Association between platelet-to-red cell distribution width ratio and all-cause mortality in critically ill patients with non-traumatic cerebral hemorrhage: a retrospective... حسب Rongrong Lu (322302)

    منشور في 2024
    "…As PRR increased, restrictive cubic splines showed a progressive decrease in the probability of all-cause mortality. …"
  15. 975

    Image 3_Efficacy and safety of tocilizumab in managing cytokine release syndrome after CD19 CAR-T therapy for relapsed or refractory B-cell acute lymphoblastic leukemia.tiff حسب Qianyi Zhou (6196383)

    منشور في 2025
    "…Purpose<p>CD19 chimeric antigen receptor T (CAR-T) cell therapy has shown promise in treating relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL), but cytokine release syndrome (CRS) remains a significant side effect.…"
  16. 976

    Table 1_Efficacy and safety of tocilizumab in managing cytokine release syndrome after CD19 CAR-T therapy for relapsed or refractory B-cell acute lymphoblastic leukemia.docx حسب Qianyi Zhou (6196383)

    منشور في 2025
    "…Purpose<p>CD19 chimeric antigen receptor T (CAR-T) cell therapy has shown promise in treating relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL), but cytokine release syndrome (CRS) remains a significant side effect.…"
  17. 977

    Image 2_Efficacy and safety of tocilizumab in managing cytokine release syndrome after CD19 CAR-T therapy for relapsed or refractory B-cell acute lymphoblastic leukemia.tiff حسب Qianyi Zhou (6196383)

    منشور في 2025
    "…Purpose<p>CD19 chimeric antigen receptor T (CAR-T) cell therapy has shown promise in treating relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL), but cytokine release syndrome (CRS) remains a significant side effect.…"
  18. 978

    Table 2_Efficacy and safety of tocilizumab in managing cytokine release syndrome after CD19 CAR-T therapy for relapsed or refractory B-cell acute lymphoblastic leukemia.doc حسب Qianyi Zhou (6196383)

    منشور في 2025
    "…Purpose<p>CD19 chimeric antigen receptor T (CAR-T) cell therapy has shown promise in treating relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL), but cytokine release syndrome (CRS) remains a significant side effect.…"
  19. 979

    Image 1_Efficacy and safety of tocilizumab in managing cytokine release syndrome after CD19 CAR-T therapy for relapsed or refractory B-cell acute lymphoblastic leukemia.tiff حسب Qianyi Zhou (6196383)

    منشور في 2025
    "…Purpose<p>CD19 chimeric antigen receptor T (CAR-T) cell therapy has shown promise in treating relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL), but cytokine release syndrome (CRS) remains a significant side effect.…"
  20. 980